A Double-blind Study to Assess the Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Participants Who Are Assessed to be at Imminent Risk for Suicide
Clinical trial NCT02133001 · COMPLETED
Trial details
- NCT number
- NCT02133001
- Sponsor
- Janssen Research & Development, LLC
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2014-05-23
- Primary completion
- 2016-02-01
- Enrollment
- 68
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.